Developing Stem Cells

Researchers across five UK universities are growing human nerve cells in the laboratory to understand why motor neurons are damaged and lost in MND, and to identify the drugs most likely to make a difference.

The cells at the centre of this work are human stem cells carrying genetic changes linked to MND. Researchers convert these into motor neurons, the nerve cells progressively lost in the disease, and study how they behave differently from healthy cells.

The stem cells carry changes in four genes known to be associated with MND: C9orf72, TARDBP, FUS, and SOD1. These cover the most common genetic forms of the disease. Researchers are also looking for shared patterns across all four. These changes could point towards treatments relevant to a broader range of people living with MND.

Each university contributes a distinct area of expertise, all working from the same cells, methods, and standards. Edinburgh focuses on how motor neurons send and receive signals. UCL examines how materials are transported inside cells. Oxford and Sheffield study how cells generate and use energy, and how they respond to stress. By combining these different lenses on the same cells, researchers build a more complete picture of what goes wrong in MND, and where a drug might intervene.

Why does this matter?

Previously, when different laboratories studied the same disease using different cell types and methods, results were difficult to compare. Promising discoveries repeatedly failed when tested in other settings, creating a bottleneck between the laboratory and the clinic that cost time no one living with MND could afford.

We were built to address exactly this kind of structural problem. Through this programme, researchers across five leading universities- King’s College London, UCL, the University of Edinburgh, the University of Oxford, and the University of Sheffield- now work from the same cells, the same methods, and the same standards. This means that findings made in one laboratory can be properly replicated at another. We’re aiming to ensure that this becomes the new standard in MND research.

What are iPSCs, and why do researchers use human cells rather than animal models?

iPSCs, or induced pluripotent stem cells, are adult cells that have been reprogrammed in the lab back into a stem-cell-like state. From here, they can then be guided to become almost any other cell type, including motor neurons. Starting from cells donated by people with the genetic changes linked to MND we can study motor neurons that carry the same disease-causing changes as a real patient, grown in the lab.

Much of the MND research that came before relied on animal models instead. When drugs showed promise in mice, many still failed when tested in people, because mouse biology isn’t the same as human biology. Human cells are far more likely to reflect what actually happens in the human body, making results from this programme more meaningful and the route to clinical testing more direct.

What could this mean in the future?

By establishing a shared, validated set of laboratory tools, this work creates a reliable pipeline for testing potential drugs before they reach clinical trials. The aim is to identify which compounds are most worth pursuing, narrowing thousands of possibilities down to those most likely to make a difference for people living with MND. It also ensures that results are reproducible and easily shared between different labs.

Who is leading this research project?

This work is led by Professor Linda Greensmith, Professor Giampietro Schiavo, Professor Bhuvaneish Selvaraj, Professor Dame Pamela Shaw, Professor Jemeen Sreedharan, and Professor Kevin Talbot, alongside a team of early-career researchers and associated scientists from across the five partner institutions.